Longeveron Inc. (LGVN)

1.7400 +0.0300 (+1.75%) 收市：04:00PM EDT

Longeveron Inc.

Life Science and Technology Park
1951 NW 7th Avenue Suite 520
Miami, FL 33136
United States
305 909 0840
https://longeveron.com

版塊: Healthcare
行業: Biotechnology
全職員工: 23

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Joshua Michael Hare FACC, M.D.	Co-Founder, Chief Science Officer & Chairman	74k	無	1963
Mr. Mohamed Wa'el Ahmed Hashad	CEO & Director	781.56k	無	1962
Ms. Lisa A. Locklear M.B.A.	Executive VP & CFO	248.38k	無	1962
Mr. Paul T. Lehr J.D.	International Executive Director, General Counsel & Secretary	554.05k	無	1968
Dr. Dan Gincel Ph.D.	Senior Vice President of Strategic Collaborations & Scientific Affairs	無	無	1971
Dr. Nataliya Agafanova M.D.	Chief Medical Officer	無	無	1970
Ms. Elly Ryu	VP & Corporate Controller	無	無	1982

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

公司管治

截至 無 止，Longeveron Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。